SAN JOSE, Calif., July 29, 2025 /PRNewswire/ — Reallusion announces the open beta of AI Render, a completely free plugin that bridges Reallusion’s intuitive 3D software—including Character Creator and iClone—with ComfyUI, the open-source, node-based interface widely regarded as the gold standard for customizable AI visual generation.

Reallusion AI Render for iClone & Character Creator with ComfyUI Integration, Available in Open Beta

AI Render enables the re-visualization of stylized 3D characters and scenes through a streamlined pipeline that supports both rapid visual exploration and consistent AI-driven re-imaging for stills and video production.

As a leading developer of real-time 3D animation tools, Reallusion empowers professionals and enthusiasts alike to step confidently into the future of 3D media creation.

The AI Render Open Beta is now live and available on the Reallusion Official Forum, where users can download the plugin, access tutorials, and connect with the development team and the active community.

Key Features

Seamless 3D & AI Integration

The foundation of AI Render is built on Reallusion’s custom node for ComfyUI, enabling a seamless two-way connection between your AI workflow and Reallusion’s 3D tools. It transfers full 3D scene data — including character poses, lighting, and camera angles — directly from iClone and Character Creator, with no technical setup required.

This integration is fully embedded into the intuitive UI of iClone and CC, allowing you to work visually and interactively while generating AI content with precision and creative control.

22 Built-In Style Presets

AI Render includes 22 professionally tuned presets across three categories: Realistic, 3D stylized, and 2D illustration. Each preset comes with optimized ControlNet settings, prompt templates, and rendering configurations for fast, consistent results.

Prompt + Reference-Based Customization

Users can guide AI results using traditional text prompts or reference images. The plugin supports IP Adapter, which allows AI to match the style and tone of any uploaded image without the need for complex prompt engineering.

Precise 3D ControlNet Guidance

Unlike AI tools that rely on 2D estimations, AI Render uses 3D-driven ControlNet inputs for stable, accurate generation across frames:

• Depth: Spatial layering and facial accuracy
• Pose: Reliable skeletal tracking, even with occlusion
• Normal: Surface lighting and shading
• Edge (Canny): Clean outlines for stylized renders

All inputs are generated directly from real-time 3D environments built in iClone and Character Creator, using Reallusion’s library of over 13,000 easily searchable, drag-and-drop assets, including characters, motions, lighting, and cameras. This makes it fast and intuitive to build structured scenes that provide AI with the consistent, frame-by-frame guidance it needs.

LoRA Dataset Creation for Character Consistency

To maintain consistent character appearances across AI videos, LoRA (Low-Rank Adaptation) training is supported. AI Render does not perform training directly but enables rapid dataset creation in iClone using batch rendering, pose libraries, and automated camera paths. Reallusion will provide project templates to assist in generating LoRA training sets for unique characters.

AI-Powered Storytelling for Character IP

AI Render is ideal for creators developing original IP characters. With Character Creator and iClone, users can design fully rigged, production-ready characters. AI Render extends their use into AI-generated movies, commercials, and stylized storytelling; all the while maintaining consistent look, expression, and style.

This isn’t just AI for visuals, your characters can now appear in AI-generated content with the continuity and expressiveness of a real actor.

Compatibility and Requirements

System Requirements:

• Operating System: Windows 10 or higher
• GPU: NVIDIA RTX 30 series (8GB minimum), AMD GPUs are not supported
• Storage: ~80 GB recommended for full model installation

• iClone 8.54 or Character Creator 4.54 (Note: Full versions are required. Trial versions are not supported.)

AI Render runs locally and is designed to work with:

• Stable Diffusion 1.5, Wan2.1 Fun 1.3B Control and Wan2.1 VACE 1.3B (default local models)
• Flux, HiDream, and FusionX are supported, but they require a more powerful hardware setup or must be run on a cloud GPU platform

Reallusion is also preparing cloud integration options for major platforms, such as RunPod and RunComfy, allowing users with modest hardware to generate high-resolution, commercial-quality outputs.

Community Challenge: Win Character Creator 5

To celebrate the launch, Reallusion is hosting a public AI Makeover Challenge from July 24 to August 22, 2025. Participants can transform their Character Creator 4 (CC4) characters using AI Render and submit images or videos for a chance to win a free copy of Character Creator 5 (CC5).

Get Started Now!

Learn more about the features of the AI Render plugin and the limited-time event in the full announcement. Visit the Reallusion Official Forum now to download AI Render, follow setup guides, and connect with the community!

This move strategically enhances Quasar’s ties to Singapore’s MedTech ecosystem and facilitates closer collaboration with global partners

SINGAPORE, July 29, 2025 /PRNewswire/ — Quasar Medical, a global leader in manufacturing interventional and minimally invasive medical devices, announced today the opening of its Global Headquarters in Singapore. This milestone marks the company’s continued growth and reinforces its commitment to advancing medical innovation worldwide.

Quasar has operated out of Hong Kong since its founding in 1988 and will continue to maintain comprehensive business operations there as part of its global presence. Relocating the headquarters from Hong Kong to Singapore strategically positions the company at the heart of Asia’s MedTech ecosystem—a region at the forefront of medical technology and healthcare innovation. The expanded two-floor facility, acquired in 2021, adds 7,000 square feet to its existing 35,000 square feet and is designed to foster collaboration, accelerate innovation, and meet the needs of customers worldwide.

“Establishing our Global Headquarters in Singapore reflects our commitment to operating where innovation thrives,” said Alex Wallstein, CEO of Quasar Medical. “Singapore is a major MedTech hub, hosting leading research institutions, top talent, and vital partners. This move will accelerate our ability to deliver advanced catheter technologies that shape the future of minimally invasive care while strengthening our collaboration with customers.”

With enhanced extrusion, braiding, balloon manufacturing, advanced assembly automation, and cutting-edge inspection systems, the new headquarters strengthens Quasar’s ability to deliver high-volume production, customized catheter solutions, exceptional quality control, and greater supply chain flexibility.

Serving as the hub for global operations, the Singapore headquarters is supported by a local team of 180 employees across engineering, operations, program management, quality, and select corporate functions. The headcount is expected to exceed 300 within three years, based on Quasar’s ambitious growth strategy and supported by Singapore’s expanding talent pool. The Singapore facility demonstrates Quasar’s sustained commitment to the region and its strategic vision for the future of medical device manufacturing.

“This move marks an exciting new chapter for Quasar in Singapore,” said Erik Trip, Site Leader. “We are expanding advanced operations, growing a strong local team, creating career opportunities, and positioning Quasar as an employer of choice within Singapore’s MedTech community.”

“Singapore welcomes Quasar Medical’s decision to establish its Global Headquarters and expand its manufacturing and innovation capabilities here. This investment reinforces Singapore’s position as a global MedTech hub where healthcare businesses can tap into our ecosystem and skilled workforce to develop and produce quality medical devices for the world. We look forward to partnering with Quasar Medical in delivering medical devices that improve lives while creating good job opportunities for Singaporeans,” said Ms. Cindy Koh, Executive Vice President, Singapore Economic Development Board.

The new headquarters reflects the remarkable progress Quasar has achieved over its 38-year journey and serves as a foundation for the next chapter—connecting people, partners, and ideas to deliver medical device solutions that improve lives worldwide.

Quasar Medical is a global Contract Development and Manufacturing Organization (CDMO) delivering end-to-end solutions for interventional and minimally invasive medical devices. With 10 global facilities and over 4,200 employees across Asia, North America, and Europe, Quasar specializes in catheter systems, balloon technologies, micro-EM sensors, and complex assemblies, delivering cost-effective scalability and unmatched speed to market. Headquartered in Singapore, the company provides fully integrated device solutions spanning design, prototyping, and scalable manufacturing. Quasar operates under ISO 13485:2016 and cGMP standards, serving leading medical device OEMs and innovators worldwide. For more information, visit www.quasarmedical.com 

PRINCETON, N.J. and TOKYO, July 29, 2025 /PRNewswire/ — Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that results of the Phase 3 ROCKET IGNITE trial of rocatinlimab, an investigational therapy targeting the OX40 receptor (OX40R) in patients with moderate-to-severe atopic dermatitis (AD), will be presented at the European Academy of Dermatology and Venereology (EADV) 2025 Annual Meeting to be held in Paris, France from September 17-20, 2025.

AD, a chronic, heterogeneous, inflammatory disease characterized by skin redness, pruritus, and pain, is driven by skin barrier disruption and T-cell-dependent inflammatory pathways. Expansion of OX40R+ pathogenic T cells leads to T-cell imbalance, a root cause of inflammatory diseases including AD.

Title: Efficacy & Safety of OX-40 Receptor Targeting with Rocatinlimab in Moderate-to-Severe Atopic Dermatitis: Results from the Phase 3 ROCKET-IGNITE Trial

Presenter: Emma Guttman-Yassky, MD, PhD

Date: Friday, September 19^th
Time: 4:40 – 4:50 pm CEST
Session: FC 08 Atopic Dermatitis
Location: Paris Convention Centre, Pavillon 7.3, Room W05-W06

About the ROCKET Phase 3 Program
ROCKET is a comprehensive, global Phase 3 clinical trial program comprised of eight studies intended to establish the safety and efficacy profile of rocatinlimab in adults and adolescents with moderate to severe atopic dermatitis (AD) as well as multiple dosing regimens.

About Moderate to Severe Atopic Dermatitis
Atopic dermatitis, the most common form of eczema, is a chronic inflammatory disease that causes excessively dry, itchy skin that can be painful. People with moderate to severe atopic dermatitis experience chronic symptoms, intensified by unpredictable flare-ups that can be painful and disruptive to everyday life. More than half of these patients report severe itching, leading to repeated scratching which can cause the skin to thicken and become vulnerable to infection. Atopic dermatitis (all severities) affects 15-20% of children and up to 10% of adults. T-cell imbalance is a root cause of atopic dermatitis, contributing to clinical manifestations including the disease’s recurring, unpredictable symptoms.

About Rocatinlimab
Rocatinlimab is an anti-OX40 human monoclonal antibody being investigated for the treatment of moderate to severe atopic dermatitis. Rocatinlimab has the potential to be the first and only T-cell rebalancing therapy that inhibits and reduces pathogenic T cells by targeting the OX40 receptor. OX40 is a co-stimulatory receptor responsible for driving systemic and local inflammatory responses in atopic dermatitis and other conditions. It has been reported that effector T cells expressing OX40 are present in the lesions of patients with atopic dermatitis and are critical in the disease pathophysiology.

Rocatinlimab is also being studied for prurigo nodularis, moderate to severe uncontrolled asthma and potentially other conditions where T-cell imbalance is a root cause of inflammation. The initial antibody was discovered in collaboration between Kyowa Kirin and La Jolla Institute for Immunology.

Rocatinlimab is currently under clinical investigation, and its safety and efficacy have not been evaluated by the U.S. FDA or any other regulatory authority.

About Kyowa Kirin
Kyowa Kirin aims to discover and deliver novel medicines and treatments with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, we have invested in drug discovery and biotechnology innovation for more than 70 years and are currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients with high unmet medical needs, such as bone & mineral, intractable hematological diseases/hemato oncology, and rare diseases. A shared commitment to our values, to sustainable growth, and to making people smile unites us across the globe. You can learn more about the business of Kyowa Kirin at: https://www.kyowakirin.com/.   

Amgen and Kyowa Kirin Collaboration
On June 1, 2021, Kyowa Kirin and Amgen entered into an agreement to jointly develop and commercialize rocatinlimab. Under the terms of the agreement, Amgen will lead the development, manufacturing, and commercialization for KHK4083/AMG 451 for all markets globally, except Japan, where Kyowa Kirin will retain all rights. If approved, the companies will co-promote the asset in the United States and Kyowa Kirin has opt-in rights to co-promote in certain other markets including Europe and Asia.

CONTACT:

Kyowa Kirin
Hiroki Nakamura: Japan
Corporate Communications Department
media@kyowakirin.com

Subrenie Thomas-Smith: North America
Sr. Director, R&D Patient Engagement & Communications
subrenie.thomas-smith.8c@kyowakirin.com

MIDDLETON, Wis., July 29, 2025 /PRNewswire/ — Leo Cancer Care, a leader in upright radiotherapy solutions, today announces that its flagship product, Marie®, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).

Marie represents a paradigm shift in the delivery of particle therapy, combining an upright patient positioning system and a CT scanner that reimagines the treatment experience for both patients and clinicians, whilst drastically reducing the size and cost compared to existing particle therapy solutions.

Marie, Leo Cancer Care’s Upright Particle Therapy Solution

“This clearance marks a major milestone not just for Leo Cancer Care, but for the future of cancer treatment,” said Stephen Towe, CEO of Leo Cancer Care. “We’ve long believed there’s a better, more human way to deliver radiotherapy. One that puts the patient at the heart of the treatment experience and embraces smarter, more compassionate design. Marie is the embodiment of that belief.”

Particle therapies such as proton and carbon ion therapy have long been considered the gold standard in radiation oncology. However, the cost, size, and complexity of conventional systems with large rotating gantries have historically limited widespread adoption.

Leo Cancer Care’s upright solution addresses these barriers. By rotating the patient rather than the beam, Marie eliminates the need for a rotating gantry, dramatically reducing infrastructure costs, simplifying installation, and expanding access to this advanced level of care.

Marie is particle beam-agnostic, meaning it’s compatible with a wide range of current and emerging treatment modalities, including proton, carbon ion, BNCT and FLASH therapies. Its upright design opens new possibilities for treatment planning and delivery, particularly for tumors in the thoracic and abdominal regions. When compared to supine treatments, evidence suggests anatomical shifts are reduced due to the gravitational direction.

Through collaborations with leading hospitals around the world, Leo Cancer Care is conducting clinical research and trials, laying a strong foundation for the widespread adoption of upright therapy as a new standard in radiotherapy.

“We are incredibly proud of the teams and collaborators who helped bring Marie to life,” added Thomas ‘Rock’ Mackie, Co-founder and Board Chairman of Leo Cancer Care. “This is just the beginning. We’re working closely with leading particle beam companies and institutions worldwide to explore how upright positioning can unlock new levels of precision and personalization in cancer care.”

Media Contact:
Fiona Redford
Head of Marketing
Leo Cancer Care
fiona@leocancercare.com

KUALA LUMPUR, Malaysia, July 29, 2025 /PRNewswire/ — Bitget, the leading cryptocurrency exchange and Web3 company, hosted a yoga retreat meet up under its Blockchain4Her initiative during Malaysia Blockchain Week 2025. The event, Blockchain4Her: Pengu Yoga Flow with Gracy Chen, the session partnered with Pudgy Penguins to connect over 25 female founders, developers, and executives for a yoga session that followed with a talk by Gracy industry discussions.

Held at The Flow Studio in KLGCC, this marked Blockchain4Her’s first sports-themed event, blending physical wellness with professional networking in an industry where women hold just 26% of leadership roles.

Gracy sharing her experiences with the attendees at the Blockchain4Her: Pengu Yoga Event

Gracy Chen,CEO at Bitget and founder of Blockchain4Her, said. “Web3 needs women at every level, not just as participants but as builders, leaders and founders,” she said. “Today was about strengthening both body and mind but also about building your professional networks.”

Blockchain4Her is growing globally, driven by its recent three-year partnership with UNICEF as part of the Game Changers Coalition. The initiative delivers blockchain and digital skills training to 300,000 young people, including girls and educators, across eight countries, with Malaysia as one of the key hubs. Through Bitget Academy, UNICEF’s first blockchain curriculum combines online modules, hands-on workshops, and game-based learning, reinforcing Blockchain4Her’s focus on delivering impact and bringing change to the lives of those involved.

The event attracted a diverse group of women from ASEAN’s Web3 scene, demonstrating strong interest in regular, substantive programming. The Pudgy Penguins collaboration advanced Bitget’s strategy of combining cultural relevance with inclusion, following their recent “Kopi Rave” side event during MYBW 2025.

About Bitget

Established in 2018, Bitget is the world’s leading cryptocurrency exchange and Web3 company. Serving over 120 million users in 150+ countries and regions, the Bitget exchange is committed to helping users trade smarter with its pioneering copy trading feature and other trading solutions, while offering real-time access to Bitcoin price, Ethereum price, and other cryptocurrency prices. Formerly known as BitKeep, Bitget Wallet is a leading non-custodial crypto wallet supporting 130+ blockchains and millions of tokens. It offers multi-chain trading, staking, payments, and direct access to 20,000+ DApps, with advanced swaps and market insights built into a single platform.

Bitget is driving crypto adoption through strategic partnerships, such as its role as the Official Crypto Partner of the World’s Top Football League, LALIGA, in EASTERN, SEA and LATAM markets, as well as a global partner of Turkish National athletes Buse Tosun Çavuşoğlu (Wrestling world champion), Samet Gümüş (Boxing gold medalist) and İlkin Aydın (Volleyball national team), to inspire the global community to embrace the future of cryptocurrency.

Aligned with its global impact strategy, Bitget has joined hands with UNICEF to support blockchain education for 1.1 million people by 2027. In the world of motorsports, Bitget is the exclusive cryptocurrency exchange partner of MotoGP™, one of the world’s most thrilling championships.

For more information, visit: Website | Twitter | Telegram | LinkedIn | Discord | Bitget Wallet

Risk Warning: Digital asset prices are subject to fluctuation and may experience significant volatility. Investors are advised to only allocate funds they can afford to lose. The value of any investment may be impacted, and there is a possibility that financial objectives may not be met, nor the principal investment recovered. Independent financial advice should always be sought, and personal financial experience and standing carefully considered. Past performance is not a reliable indicator of future results. Bitget accepts no liability for any potential losses incurred. Nothing contained herein should be construed as financial advice. For further information, please refer to our Terms of Use.

SINGAPORE, July 29, 2025 /PRNewswire/ — On July 27, 2025, POP MART successfully hosted a 5km themed run in Singapore, drawing over 3,000 enthusiastic participants. As part of the annual Lazada Run series, the event was held against the scenic backdrop of Marina Barrage, where fans crossed the finish line and engaged in photo ops, mini-games, and immersive experiences with Twinkle Twinkle, POP MART’s beloved IP character in Southeast Asia.

This partnership marks a key milestone in POP MART’s year-round collaboration with Southeast Asia’s leading e-commerce platform Lazada. Lazada Run, first launched in 2023, is one of the platform’s flagship initiatives, spanning Indonesia, Malaysia, the Philippines, Singapore, Thailand, and Vietnam. After two years of successful operation, POP MART joined Lazada Run in 2025 to bring a more dynamic, immersive IP experience to runners across the region, integrating into multiple physical and digital touchpoints.

To date, POP MART has successfully completed the Philippines leg on June 1, the Vietnam race on July 13, and now the Singapore run on July 27. Each location saw overwhelming fan enthusiasm, with the Twinkle Twinkle experience zone emerging as a major highlight and social media hotspot, significantly enhancing brand visibility and emotional resonance. At the Singapore event, POP MART further enriched the on-site experience by introducing a giant Twinkle Twinkle inflatable at the Runners’ Village, drawing crowds for photos and fan interactions. A “Best Dressed” contest also encouraged runners to showcase POP MART-inspired looks — from playful costumes to limited-edition merch — celebrating creativity and deepening fan-brand connection.

In addition to Lazada Run, POP MART and Lazada will co-launch the Super Brand Day campaign in late August across five Southeast Asian countries — Singapore, Malaysia, Thailand, the Philippines, and Vietnam, which will also coincide with the opening of PTS (Pop Toy Show) events in Singapore later, combining a seamless online and offline exposure. With Lazada offering full-platform promotional support, including exclusive gifts and trending product launches, the collaboration aims to drive both engagement and sales at scale.

Looking ahead, the Lazada Run x POP MART tour will continue in Malaysia, Thailand, and Indonesia from October to December. Through this year-long partnership, POP MART not only strengthens its IP exposure in Southeast Asia but also builds emotional resonance with emerging audiences — laying the groundwork for its next generation of global breakout characters.